Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00262-010-0870-9.

Title:
Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer | Cancer Immunology, Immunotherapy
Description:
Despite spontaneous or vaccination-induced immune responses, pancreatic cancer remains one of the most deadly immunotherapy-resistant malignancies. We sought to comprehend the spectrum of pancreatic tumor-associated antigens (pTAAs) and to assess the clinical relevance of their immunogenicity. An autologous SEREX-based screening of a cDNA library constructed from a pancreatic T3N0M0/GIII specimen belonging to a long-term survivor (36 months) revealed 18 immunogenic pTAA. RT-PCR analysis displayed broad distribution of the identified antigens among normal human tissues. PNLIPRP2 and MIA demonstrated the most distinct pancreatic cancer-specific patterns. ELISA-based screening of sera for corresponding autoantibodies revealed that although significantly increased, the immunogenicity of these molecules was not a common feature in pancreatic cancer. QRT-PCR and immunohistochemistry characterized PNLIPRP2 as a robust acinar cell-specific marker whose decreased expression mirrored the disappearance of parenchyma in the diseased organ, but was not related to the presence of PNLIPRP2 autoantibodies. Analyses of MIA—known to be preferentially expressed in malignant cells—surprisingly revealed an inverse correlation between intratumoral gene expression and the emergence of autoantibodies. MIAhigh patients were autoantibody-negative and had shorter median survival when compared with autoantibody-positive MIAlow patients (12 vs. 34 months). The observed pTAA spectrum comprised molecules associated with acinar, stromal and malignant structures, thus presenting novel targets for tumor cell-specific therapies as well as for approaches based on the bystander effects. Applying the concept of cancer immunoediting to interpret relationships between gene expression, antitumor immune responses, and clinical outcome might better discriminate between past and ongoing immune responses, consequently enabling prognostic stratification of patients and individual adjustment of immunotherapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, google, scholar, pubmed, article, cas, pancreatic, patients, immune, res, antigens, immunol, identification, response, cell, human, expression, tumor, immunotherapy, int, clin, antigen, heidelberg, responses, protein, melanoma, search, immunology, clinical, autoantibodies, antibody, peptide, immunother, med, privacy, cookies, content, analysis, giese, mia, access, humoral, antibodies, carcinoma, activity, data, information, publish, immunogenicity, outcome,

Topics {✒️}

functional tumor-reactive t-cells t-cell-mediated antitumor immunity month download article/chapter cancer-testis antigen ny-eso-1 hepatoma-derived growth factor ny-eso-1 epitopes presented deadly immunotherapy-resistant malignancies tumor cell-specific therapies ny-eso-1-expressing melanoma a2-binding peptide epitopes autologous serex-based screening autoantibody-mediated immune response chronic pancreatitis tnf-dependent bystander eradication autoantibody-positive mialow patients article cancer immunology cdna library constructed circulating anti-p53 antibodies malignant cells—surprisingly revealed vaccination-induced immune responses anti-p53 antibodies increases full article pdf muc1 vaccine composed privacy choices/manage cookies antitumor immune responses specific vimentin isoform breast cancer library human histocompatibility antigen elicits antibody responses immune-mediated dormancy melanoma cell migration immunohistochemistry characterized pnliprp2 excellent technical support melanoma inhibitory activity human breast cancer ongoing immune responses tolerogenic cell death muc1 peptide vaccination normal human tissues cancer testis antigen cellular antimesothelin immunity effective immune response cellular immune response immune response manifested antiendothelial cell antibodies pancreatic ductal adenocarcinoma pancreatic cancer remains pancreatic cancer cells metastatic pancreatic cancer humoral immune responses

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer
         description:Despite spontaneous or vaccination-induced immune responses, pancreatic cancer remains one of the most deadly immunotherapy-resistant malignancies. We sought to comprehend the spectrum of pancreatic tumor-associated antigens (pTAAs) and to assess the clinical relevance of their immunogenicity. An autologous SEREX-based screening of a cDNA library constructed from a pancreatic T3N0M0/GIII specimen belonging to a long-term survivor (36 months) revealed 18 immunogenic pTAA. RT-PCR analysis displayed broad distribution of the identified antigens among normal human tissues. PNLIPRP2 and MIA demonstrated the most distinct pancreatic cancer-specific patterns. ELISA-based screening of sera for corresponding autoantibodies revealed that although significantly increased, the immunogenicity of these molecules was not a common feature in pancreatic cancer. QRT-PCR and immunohistochemistry characterized PNLIPRP2 as a robust acinar cell-specific marker whose decreased expression mirrored the disappearance of parenchyma in the diseased organ, but was not related to the presence of PNLIPRP2 autoantibodies. Analyses of MIA—known to be preferentially expressed in malignant cells—surprisingly revealed an inverse correlation between intratumoral gene expression and the emergence of autoantibodies. MIAhigh patients were autoantibody-negative and had shorter median survival when compared with autoantibody-positive MIAlow patients (12 vs. 34 months). The observed pTAA spectrum comprised molecules associated with acinar, stromal and malignant structures, thus presenting novel targets for tumor cell-specific therapies as well as for approaches based on the bystander effects. Applying the concept of cancer immunoediting to interpret relationships between gene expression, antitumor immune responses, and clinical outcome might better discriminate between past and ongoing immune responses, consequently enabling prognostic stratification of patients and individual adjustment of immunotherapy.
         datePublished:2010-06-01T00:00:00Z
         dateModified:2010-06-01T00:00:00Z
         pageStart:1389
         pageEnd:1400
         sameAs:https://doi.org/10.1007/s00262-010-0870-9
         keywords:
            Pancreatic cancer
            Immunoediting
            SEREX
            PNLIPRP2
            MIA
            Antibody
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-010-0870-9/MediaObjects/262_2010_870_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-010-0870-9/MediaObjects/262_2010_870_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-010-0870-9/MediaObjects/262_2010_870_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-010-0870-9/MediaObjects/262_2010_870_Fig4_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:59
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. Heller
               affiliation:
                     name:University Hospital Heidelberg
                     address:
                        name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:I. Zörnig
               affiliation:
                     name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
                     address:
                        name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:T. Müller
               affiliation:
                     name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
                     address:
                        name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:K. Giorgadze
               affiliation:
                     name:University Hospital Heidelberg
                     address:
                        name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Frei
               affiliation:
                     name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
                     address:
                        name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:T. Giese
               affiliation:
                     name:University Hospital Heidelberg
                     address:
                        name:Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Bergmann
               affiliation:
                     name:University Hospital Heidelberg
                     address:
                        name:Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. Schmidt
               affiliation:
                     name:University Hospital Heidelberg
                     address:
                        name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. Werner
               affiliation:
                     name:University Hospital Heidelberg
                     address:
                        name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. W. Buchler
               affiliation:
                     name:University Hospital Heidelberg
                     address:
                        name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. Jaeger
               affiliation:
                     name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
                     address:
                        name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. A. Giese
               affiliation:
                     name:University Hospital Heidelberg
                     address:
                        name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer
      description:Despite spontaneous or vaccination-induced immune responses, pancreatic cancer remains one of the most deadly immunotherapy-resistant malignancies. We sought to comprehend the spectrum of pancreatic tumor-associated antigens (pTAAs) and to assess the clinical relevance of their immunogenicity. An autologous SEREX-based screening of a cDNA library constructed from a pancreatic T3N0M0/GIII specimen belonging to a long-term survivor (36 months) revealed 18 immunogenic pTAA. RT-PCR analysis displayed broad distribution of the identified antigens among normal human tissues. PNLIPRP2 and MIA demonstrated the most distinct pancreatic cancer-specific patterns. ELISA-based screening of sera for corresponding autoantibodies revealed that although significantly increased, the immunogenicity of these molecules was not a common feature in pancreatic cancer. QRT-PCR and immunohistochemistry characterized PNLIPRP2 as a robust acinar cell-specific marker whose decreased expression mirrored the disappearance of parenchyma in the diseased organ, but was not related to the presence of PNLIPRP2 autoantibodies. Analyses of MIA—known to be preferentially expressed in malignant cells—surprisingly revealed an inverse correlation between intratumoral gene expression and the emergence of autoantibodies. MIAhigh patients were autoantibody-negative and had shorter median survival when compared with autoantibody-positive MIAlow patients (12 vs. 34 months). The observed pTAA spectrum comprised molecules associated with acinar, stromal and malignant structures, thus presenting novel targets for tumor cell-specific therapies as well as for approaches based on the bystander effects. Applying the concept of cancer immunoediting to interpret relationships between gene expression, antitumor immune responses, and clinical outcome might better discriminate between past and ongoing immune responses, consequently enabling prognostic stratification of patients and individual adjustment of immunotherapy.
      datePublished:2010-06-01T00:00:00Z
      dateModified:2010-06-01T00:00:00Z
      pageStart:1389
      pageEnd:1400
      sameAs:https://doi.org/10.1007/s00262-010-0870-9
      keywords:
         Pancreatic cancer
         Immunoediting
         SEREX
         PNLIPRP2
         MIA
         Antibody
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-010-0870-9/MediaObjects/262_2010_870_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-010-0870-9/MediaObjects/262_2010_870_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-010-0870-9/MediaObjects/262_2010_870_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-010-0870-9/MediaObjects/262_2010_870_Fig4_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:59
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. Heller
            affiliation:
                  name:University Hospital Heidelberg
                  address:
                     name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:I. Zörnig
            affiliation:
                  name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
                  address:
                     name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T. Müller
            affiliation:
                  name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
                  address:
                     name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:K. Giorgadze
            affiliation:
                  name:University Hospital Heidelberg
                  address:
                     name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Frei
            affiliation:
                  name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
                  address:
                     name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T. Giese
            affiliation:
                  name:University Hospital Heidelberg
                  address:
                     name:Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Bergmann
            affiliation:
                  name:University Hospital Heidelberg
                  address:
                     name:Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. Schmidt
            affiliation:
                  name:University Hospital Heidelberg
                  address:
                     name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. Werner
            affiliation:
                  name:University Hospital Heidelberg
                  address:
                     name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. W. Buchler
            affiliation:
                  name:University Hospital Heidelberg
                  address:
                     name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. Jaeger
            affiliation:
                  name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
                  address:
                     name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. A. Giese
            affiliation:
                  name:University Hospital Heidelberg
                  address:
                     name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:59
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospital Heidelberg
      address:
         name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
      address:
         name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
      address:
         name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital Heidelberg
      address:
         name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
      address:
         name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital Heidelberg
      address:
         name:Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital Heidelberg
      address:
         name:Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital Heidelberg
      address:
         name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital Heidelberg
      address:
         name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital Heidelberg
      address:
         name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
      address:
         name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital Heidelberg
      address:
         name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. Heller
      affiliation:
            name:University Hospital Heidelberg
            address:
               name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:I. Zörnig
      affiliation:
            name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
            address:
               name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:T. Müller
      affiliation:
            name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
            address:
               name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:K. Giorgadze
      affiliation:
            name:University Hospital Heidelberg
            address:
               name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:C. Frei
      affiliation:
            name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
            address:
               name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:T. Giese
      affiliation:
            name:University Hospital Heidelberg
            address:
               name:Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:F. Bergmann
      affiliation:
            name:University Hospital Heidelberg
            address:
               name:Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:J. Schmidt
      affiliation:
            name:University Hospital Heidelberg
            address:
               name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:J. Werner
      affiliation:
            name:University Hospital Heidelberg
            address:
               name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:M. W. Buchler
      affiliation:
            name:University Hospital Heidelberg
            address:
               name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:D. Jaeger
      affiliation:
            name:National Centre of Tumor Diseases (NCT), University Hospital Heidelberg
            address:
               name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:N. A. Giese
      affiliation:
            name:University Hospital Heidelberg
            address:
               name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
      name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
      name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
      name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
      name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
      name:Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany
      name:Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
      name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
      name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
      name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
      name:Medical Oncology, National Centre of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
      name:Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(239)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.07s.